Business Wire

Great Northern Hydroponics Projects CA$150,000 in Annual Savings After Fluence LED Implementation

9.2.2021 16:00:00 EET | Business Wire | Press release

Share

Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial food and cannabis production, and Great Northern Hydroponics, an Ontario, Canada-based greenhouse growing more than 10 varieties of tomatoes, announced today that the companies’ collaborative LED implementation is projected to save an estimated 150,000 Canadian dollars in annual operating costs for the greenhouse. The project also qualified for an incentive through the Independent Electricity System Operator’s (IESO) Save on Energy Retrofit program that will significantly reduce the upfront costs of upgrading its lighting technology.

Great Northern Hydroponics’ 70-acre facility produces 20 million pounds of premium tomatoes annually. Its hydroponic greenhouses create optimum growing conditions through a sophisticated climate control system as well as a biologically controlled environment to prevent pest manifestations. Fluence’s LED technology was retrofitted across 10 acres of the facility’s tomato glasshouse. At the helm of Great Northern Hydroponics’ growing operation are Guido van het Hof, the company’s president and general manager, and Dean Bernardes, vice president of operations. Both hold decades of experience growing high-quality crops using the industry’s most advanced cultivation technology.

“We’ve been growing tomatoes for more than 20 years,” Van het Hof said. “As one of the first growers in our region to illuminate crops in a commercial environment, we’ve been immersed in researching and optimizing spectral strategies for plant growth and quality. Since the onset of LED technology, I’ve been particularly curious about how broad-spectrum LEDs could affect plant development. Based on our years of research and trialing, we’ve discovered that crops grow beautifully—with higher yields and fruit weights—under broad-spectrum light.”

Van het Hof’s multiyear commitment to researching the latest advancements and strategies for LED horticulture lighting rivals leading research universities and some of the world’s largest cultivators. In his pursuit to identify the optimal spectral strategy for vine crop production, Van het Hof spearheaded various trials with high-pressure sodium fixtures as well as LED technology. Throughout his decade-long exploration, Van het Hof has recorded significant advantages under broad-spectrum LED technology, reporting an increase in biomass and fruit production as well as significant energy savings—reductions which enabled the Great Northern Hydroponics team to leverage the Save on Energy Retrofit program offering growers incentives for energy-efficient lighting upgrades.

“Great Northern Hydroponics has always been a pioneer in leveraging horticulture technology and innovative cultivation methods,” said Steve Graves, vice president of business development for Fluence and long-time collaborator with Van het Hof. “Our work with Guido has informed some of our most important product advancements for vine crop growers throughout the world. Guido and his team at Great Northern Hydroponics have reinforced the validity and efficacy of LED lighting in greenhouse environments.”

Through Fluence’s utility rebate coordination program, the company assists growers with identifying, applying for and, in some cases, creating rebate programs in a facility’s respective region. With Great Northern Hydroponics’ lighting upgrade supported by the Save on Energy Retrofit program incentive, Van het Hof estimates the business will save approximately CA$150,000 in annual operational costs by replacing its high-pressure sodium lighting with Fluence’s LED technology.

“LED technology is proving to be superior across all categories,” Van het Hof added. “Our plants are flourishing under broad-spectrum lighting, our operational costs are decreasing and our staff is enjoying working with white light versus harsher, redder lights. It’s a win-win for everyone.”

For more information on Fluence and its rebate services, visit www.fluence.science.

About Fluence by OSRAM

Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM, creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit https://fluence.science.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Fluence,
Emma Chase
emma@redfancommunications.com
C: 512-917-4319

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release

PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release

Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release

Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye